Zevra Therapeutics, Inc.
ZVRA
$9.98
-$0.21-2.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 30.93% | 0.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 30.93% | 0.70% | |||
| Cost of Revenue | 22.78% | -90.00% | |||
| Gross Profit | 31.34% | 83.86% | |||
| SG&A Expenses | 20.76% | -18.51% | |||
| Depreciation & Amortization | 0.32% | -80.51% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.18% | -42.63% | |||
| Operating Income | 124.84% | 133.60% | |||
| Income Before Tax | 1,396.42% | -101.27% | |||
| Income Tax Expenses | 215.70% | -119.69% | |||
| Earnings from Continuing Operations | 2,336.21% | -100.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2,336.21% | -100.73% | |||
| EBIT | 124.84% | 133.60% | |||
| EBITDA | 113.38% | 142.47% | |||
| EPS Basic | 2,262.89% | -100.77% | |||
| Normalized Basic EPS | 1,238.21% | 91.52% | |||
| EPS Diluted | 2,048.00% | -100.81% | |||
| Normalized Diluted EPS | 1,193.50% | 91.28% | |||
| Average Basic Shares Outstanding | 0.80% | 2.14% | |||
| Average Diluted Shares Outstanding | 4.92% | -0.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||